Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Resalis Therapeutics Announces Seed Financing of \u20ac10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Resalis Therapeutics Raises \u20ac10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"IND Enabling","country":"ITALY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Resalis Therapeutics

    Menu

    Resalis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Resalis Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity

              Details:

              The proceeds will be used to initiate and complete the first-in-human Phase 1 clinical trial and reach Phase 2 readiness for Resalis’ lead program, RES-010, a non-coding RNA-based compound, in obesity.

              Lead Product(s): RES-010

              Therapeutic Area: Nutrition and Weight Loss Product Name: RES-010

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sunstone Life Science Ventures

              Deal Size: $11.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Resalis Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases

              Details:

              The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).

              Lead Product(s): Non-Coding RNA-Based Therapy

              Therapeutic Area: Nutrition and Weight Loss Product Name: RES-010

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Claris Ventures

              Deal Size: $10.6 million Upfront Cash: Undisclosed

              Deal Type: Financing February 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY